Undisclosed Organ Engineering Program(s)
Prevention of Organ Transplant Rejection
PreclinicalActive
Key Facts
About Allogenetics
Allogenetics is a preclinical-stage biotech founded in 2021, developing a first-in-class therapeutic platform to engineer donor organs for immunological invisibility. The company's core technology involves the ex vivo genetic modification of organs to silence the expression of Human Leukocyte Antigen (HLA) proteins, thereby preventing recognition and rejection by the recipient's immune system without the need for chronic immunosuppression. Founded by leading experts in transplant engineering and immunology, the company is based on pioneering academic research. If successful, this approach could fundamentally transform the standard of care in solid organ transplantation.
View full company profile